Management of Low Hemoglobin, RBC, and WBC Count

Initial Diagnostic Workup

A thorough diagnostic evaluation should include a complete drug exposure history to identify medication-related causes, as recommended by the American Society of Clinical Oncology 1
Careful review of peripheral blood smear and possibly bone marrow examination is necessary for accurate diagnosis, according to the American Society of Clinical Oncology 2, 1
Assessment for iron, folate, and vitamin B12 deficiency is crucial, as suggested by the European Society for Medical Oncology 2, 3
Evaluation for occult blood loss and renal insufficiency should be performed, as recommended by the American Society of Clinical Oncology 2
Coombs testing for patients with suspected autoimmune hemolytic anemia is essential, according to the American Society of Clinical Oncology 2
Evaluation for infectious causes of cytopenia should be considered, as suggested by the Infectious Diseases Society of America 1
Assessment for bone marrow failure syndromes is necessary, according to the American Society of Hematology 1

Oral iron supplementation is recommended, with a dosage of ferrous sulfate 200 mg three times daily, as suggested by the European Society for Medical Oncology 3
Iron therapy should be continued for three months after correction of anemia to replenish iron stores, according to the European Society for Medical Oncology 3
Ascorbic acid may be added to enhance iron absorption, as recommended by the European Society for Medical Oncology 3

Erythropoiesis-stimulating agents (ESAs) such as epoetin or darbepoetin are recommended treatment options for patients with hemoglobin approaching or below 10 g/dL, according to the American Society of Clinical Oncology 2, 4
Red blood cell transfusion is also an option depending on the severity of anemia or clinical circumstances, as suggested by the American Society of Clinical Oncology 2, 4
ESAs should be used with caution in patients with high risk of thromboembolic events, as recommended by the American Society of Clinical Oncology 2, 4

RBC transfusion is recommended only when hemoglobin concentration decreases to < 7.0 g/dL in hemodynamically stable patients, according to the Society of Critical Care Medicine 5, 6
The minimum number of RBC units necessary to relieve symptoms or return hemoglobin to a safe range (7-8 g/dL) should be transfused, as recommended by the American Society of Clinical Oncology 1

For Grade 2 immune-related cytopenias, immune checkpoint inhibitors should be held and prednisone 0.5-1 mg/kg/day may be considered, as suggested by the American Society of Clinical Oncology 1
For Grade 3-4 immune-related cytopenias, immune checkpoint inhibitors should be permanently discontinued, and prednisone 1-2 mg/kg/day may be administered, according to the American Society of Clinical Oncology 1
Severe refractory cases may require rituximab, IVIG, cyclosporine, infliximab, mycophenolate mofetil, or anti-thymocyte globulin, as recommended by the American Society of Clinical Oncology 1

Hematology consultation is essential for suspected bone marrow failure syndromes, according to the American Society of Hematology 7
Evaluation for hematopoietic stem cell transplantation may be considered in appropriate candidates, as suggested by the American Society of Hematology 7

Erythropoietin should not be used for treatment of anemia associated with sepsis, as recommended by the Society of Critical Care Medicine 5
RBC transfusion should occur only when hemoglobin concentration decreases to < 7.0 g/dL in patients with sepsis, according to the Society of Critical Care Medicine 5
Asymptomatic patients with methemoglobinemia can be monitored without treatment, while symptomatic patients should receive methylene blue (1-2 mg/kg IV), as recommended by the American Society of Hematology 8
Methylene blue should be avoided in G6PD-deficient patients, according to the American Society of Hematology 8

Hemoglobin levels should be monitored weekly until stable, then less frequently, as recommended by the American Society of Clinical Oncology 1
Patients on iron therapy should be monitored for at least one year after normalization, according to the European Society for Medical Oncology 3
Additional oral iron should be given if hemoglobin or MCV falls below normal during follow-up, as suggested by the European Society for Medical Oncology 3

Hemoglobin concentration should not be relied upon solely as a "transfusion trigger"; consider the patient's clinical condition, as recommended by the Society of Critical Care Medicine 6
Erythropoietin should not be used in patients with hemoglobin levels >10 g/dL due to increased risk of thromboembolic events, according to the American Society of Clinical Oncology 2, 4
Invasive procedures should be avoided in patients with coagulopathy until it is corrected, as recommended by the American Society of Hematology 9
Multiple myeloma patients treated with thalidomide or lenalidomide plus corticosteroids are at increased risk for thromboembolic events if given ESAs, according to the American Society of Clinical Oncology 4